Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)–tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma
Year: 2016
Type: article
Study design: Observational Study
Source: Annals of Oncology
Authors: R. Nadal, A. Amin, D.M. Geynisman, M.H. Voss, M. Weinstock, J. Doyle, Z. Zhang, A. Viudez, E.R. Plimack, D.F. McDermott, R. Motzer, B. Rini, H.J. Hammers
Institutions: Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Levine Cancer Institute, Fox Chase Cancer Center, Temple University Health System, Memorial Sloan Kettering Cancer Center, Beth Israel Deaconess Medical Center, Harvard University, Dana-Farber/Harvard Cancer Center, Cleveland Clinic
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2317632169